Friday, September 26, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Freeport-McMoRan Shares Plunge Following Mine Tragedy and Production Halt

Robert Sasse by Robert Sasse
September 26, 2025
in Analysis, Commodities, Earnings, Industrial
0
Freeport-McMoRan Stock
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

A fatal incident at a key Indonesian mining operation has cast a shadow over Freeport-McMoRan’s growth trajectory, triggering a sharp decline in its stock value. The company was forced to declare force majeure on copper deliveries after a mudslide halted production at a critical facility, leading to a significant reduction in its sales forecast for the third quarter.

Market Reaction and Analyst Downgrades

The financial impact was immediate and severe. Freeport-McMoRan’s stock plummeted approximately 22 percent over a two-day period as investors reacted to the news. The market response was echoed by a wave of analyst downgrades. Several major financial institutions revised their recommendations and price targets downward, reflecting heightened risk perceptions.

  • BofA Securities adjusted its rating to “Neutral” and set a new price target of $42.00.
  • Scotiabank downgraded the stock to “Sector Perform,” slashing its target from $55 to $45.
  • UBS maintained a “Neutral” stance but reduced its target price to $42.50 from $50.00.

A contrasting view came from Bernstein, which surprisingly upgraded the shares to “Outperform,” citing an oversold position. However, the prevailing sentiment among market experts is one of caution. The timeline for a full recovery appears extended, with pre-incident production levels not anticipated until 2027. Preliminary estimates suggest Indonesian output for 2026 could be around 35 percent lower.

Should investors sell immediately? Or is it worth buying Freeport-McMoRan?

Operational Setback and Global Supply Impact

The crisis stems from a tragic mudflow on September 8 at the Grasberg Block Cave mine, which resulted in the death of two miners and left five others missing. This facility is of paramount importance, accounting for an estimated 70 percent of the company’s planned copper and gold production through 2029. With operations suspended indefinitely, Freeport-McMoRan now expects its Q3 copper sales to be roughly 4 percent lower, and gold sales about 6 percent lower, than its July forecast.

The disruption at one of the world’s largest copper mines has reverberated through global commodity markets, pushing copper prices upward due to anticipated supply constraints. The path to resuming operations remains uncertain. While other underground sections of the Grasberg complex might commence operations by the fourth quarter of 2025, a phased restart of the damaged Block Cave mine is not expected before the first half of 2026. An ongoing investigation by Indonesian authorities, which points to heavy rainfall as a potential cause, will be critical in determining the final schedule.

For shareholders, the situation remains fluid. The stock’s recovery is now directly tied to demonstrable progress in restoring production at the Indonesian site. Every subsequent corporate update and the conclusion of the official investigation will be scrutinized for signs of a rebound.

Ad

Freeport-McMoRan Stock: Buy or Sell?! New Freeport-McMoRan Analysis from September 26 delivers the answer:

The latest Freeport-McMoRan figures speak for themselves: Urgent action needed for Freeport-McMoRan investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 26.

Freeport-McMoRan: Buy or sell? Read more here...

Tags: Freeport-McMoRan
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Nike Stock
Analysis

Nike’s Strategic Pivot: High-Stakes SKIMS Collaboration Launches

September 26, 2025
BioNTech Stock
Analysis

BioNTech Shares Surge on Regulatory Win and Analyst Confidence

September 26, 2025
Bloom Energy Stock
Analysis

Bloom Energy Shares Plunge as Analyst Downgrade Questions AI-Driven Rally

September 26, 2025
Next Post
S&P 500 Stock

Strong Economic Data Sparks Sell-Off in S&P 500

Cardiff Oncology Stock

Cardiff Oncology Shares Face Sustained Selling Pressure

Fannie Mae Stock

Political Headwinds Buffet Fannie Mae's Path to Privatization

Recommended

Technology Quantum computing Market Capitalization

Options Activity Signals Optimism for SentinelOne

2 years ago
Ströer Stock

Ströer Stock: Q3 Slump Tests Annual Targets

1 month ago

A Day of History March 6 2024

2 years ago
Alphabet Stock

Landmark Ruling Secures Alphabet’s Core Business Model

2 weeks ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

AAPL Adobe Alibaba Alphabet Amazon AMD Apple ASML BA BigBear.ai BioNTech Broadcom Coinbase Eli Lilly Fiserv Hims & Hers IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Opendoor Oracle Oxford Lane Capital Palantir PayPal Pepsi Red Cat Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla TSLA Unitedhealth Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Bloom Energy Shares Plunge as Analyst Downgrade Questions AI-Driven Rally

Moderna’s UK Expansion Fails to Impress as Shares Decline

UnitedHealth Navigates Legal Challenges While Pursuing Growth Initiatives

Political Headwinds Buffet Fannie Mae’s Path to Privatization

Cardiff Oncology Shares Face Sustained Selling Pressure

Strong Economic Data Sparks Sell-Off in S&P 500

Trending

Nike Stock
Analysis

Nike’s Strategic Pivot: High-Stakes SKIMS Collaboration Launches

by Robert Sasse
September 26, 2025
0

Nike is making a bold strategic move with the highly anticipated launch of its NikeSKIMS collaboration today....

Realty Income Stock

Realty Income Secures $800 Million Through Dual-Tranche Bond Offering

September 26, 2025
BioNTech Stock

BioNTech Shares Surge on Regulatory Win and Analyst Confidence

September 26, 2025
Bloom Energy Stock

Bloom Energy Shares Plunge as Analyst Downgrade Questions AI-Driven Rally

September 26, 2025
Moderna Stock

Moderna’s UK Expansion Fails to Impress as Shares Decline

September 26, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Nike’s Strategic Pivot: High-Stakes SKIMS Collaboration Launches
  • Realty Income Secures $800 Million Through Dual-Tranche Bond Offering
  • BioNTech Shares Surge on Regulatory Win and Analyst Confidence

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com